Cookson Peirce & Co. Inc. Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Cookson Peirce & Co. Inc. acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 6,213 shares of the biopharmaceutical company’s stock, valued at approximately $486,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Measured Wealth Private Client Group LLC grew its holdings in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares during the last quarter. Abel Hall LLC increased its stake in shares of Halozyme Therapeutics by 4.2% in the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 129 shares during the period. StoneX Group Inc. raised its holdings in Halozyme Therapeutics by 3.8% during the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 132 shares during the last quarter. Twin Capital Management Inc. raised its holdings in Halozyme Therapeutics by 1.4% during the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 161 shares during the last quarter. Finally, Coldstream Capital Management Inc. boosted its position in Halozyme Therapeutics by 1.9% during the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock valued at $654,000 after buying an additional 165 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HALO. Morgan Stanley cut their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $83.00 to $110.00 in a report on Friday, August 7th. UBS Group reissued a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $105.35 on Monday. The stock has a fifty day moving average of $87.01 and a 200 day moving average of $74.74. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $109.66. The firm has a market capitalization of $11.96 billion, a price-to-earnings ratio of 31.45, a PEG ratio of 0.42 and a beta of 0.85. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter in the previous year, the business posted $1.54 earnings per share. The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Insider Activity

In related news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 42,478 shares of company stock valued at $3,767,304. Corporate insiders own 2.50% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.